Friedrich Grimminger Selected Research

5,6-epoxy-8,11,14-eicosatrienoic acid

1/2020

Cytochrome P450 epoxygenase-derived 5,6-epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Friedrich Grimminger Research Topics

Disease

92	Pulmonary Hypertension 01/2022 - 01/2002
61	Hypoxia (Hypoxemia) 01/2022 - 01/2002
47	Pulmonary Arterial Hypertension 01/2021 - 04/2002
31	Vascular Remodeling 02/2021 - 04/2004
25	Neoplasms (Cancer) 02/2022 - 08/2005
16	Fibrosis (Cirrhosis) 03/2018 - 09/2002
12	Lung Neoplasms (Lung Cancer) 01/2022 - 11/2009
12	Cardiomegaly (Heart Hypertrophy) 01/2019 - 01/2004
11	Pulmonary Fibrosis (Fibrosing Alveolitis) 03/2022 - 12/2003
10	Inflammation (Inflammations) 02/2022 - 06/2002
10	Emphysema 01/2022 - 10/2011
9	Familial Primary Pulmonary Hypertension 01/2022 - 07/2005
8	Sepsis (Septicemia) 10/2018 - 06/2002
8	Hypertrophy 03/2018 - 08/2007
7	Idiopathic Pulmonary Fibrosis 01/2022 - 01/2008
7	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 03/2014
7	Right Ventricular Hypertrophy 01/2021 - 01/2010
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2018 - 10/2009
6	Neoplasm Metastasis (Metastasis) 02/2022 - 02/2015
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2002
5	Body Weight (Weight, Body) 12/2018 - 12/2003
5	Lung Diseases (Lung Disease) 11/2015 - 09/2004
5	Lung Injury 05/2015 - 01/2004
4	Pulmonary Heart Disease (Cor Pulmonale) 01/2022 - 01/2004
4	Infections 10/2018 - 03/2003
4	Hypertension (High Blood Pressure) 11/2015 - 12/2013
4	Pneumonia (Pneumonitis) 05/2015 - 08/2002
4	Edema (Dropsy) 05/2008 - 03/2003
4	Septic Shock (Toxic Shock Syndrome) 04/2006 - 01/2003
3	Hypercapnia 01/2021 - 11/2009
3	Heart Diseases (Heart Disease) 01/2020 - 09/2005
3	Ventricular Remodeling 03/2018 - 02/2012
3	Vascular Diseases (Vascular Disease) 11/2015 - 10/2002
3	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2015 - 07/2002

Drug/Important Bio-Agent (IBA)

24	MonocrotalineIBA 02/2021 - 01/2004
21	Sildenafil Citrate (Viagra)FDA Link 11/2017 - 04/2002
20	Proteins (Proteins, Gene)FDA Link 02/2022 - 05/2004
16	riociguatIBA 01/2019 - 03/2010
16	Soluble Guanylyl CyclaseIBA 05/2017 - 01/2006
15	Oxygen (Dioxygen)IBA 12/2018 - 01/2002
14	Iloprost (Ventavis)FDA Link 01/2016 - 01/2002
12	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 09/2002
12	CytokinesIBA 01/2020 - 06/2002
10	NADPH Oxidases (NAD(P)H oxidase)IBA 07/2020 - 05/2004
10	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2015 - 11/2002
10	Imatinib Mesylate (Gleevec)FDA Link 03/2013 - 09/2005
9	Bleomycin (Blenoxane)FDA LinkGeneric 03/2022 - 12/2003
9	ProstaglandinsIBA 03/2017 - 06/2002
8	SmokeIBA 01/2022 - 10/2011
8	Transcription Factors (Transcription Factor)IBA 01/2021 - 10/2002
8	Semaxinib (SU5416)IBA 01/2021 - 09/2008
8	Phosphodiesterase 5 InhibitorsIBA 11/2017 - 01/2004
7	Phosphotransferases (Kinase)IBA 01/2021 - 11/2008
7	15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidIBA 02/2011 - 12/2003
6	Superoxides (Superoxide)IBA 01/2020 - 12/2003
6	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 06/2009
6	treprostinil FDA Link 10/2018 - 01/2006
6	EmulsionsIBA 05/2015 - 05/2002
6	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 05/2015 - 10/2005
6	Messenger RNA (mRNA)IBA 12/2013 - 03/2002
6	Small Interfering RNA (siRNA)IBA 12/2013 - 05/2005
6	Vasoconstrictor AgentsIBA 06/2011 - 07/2005
6	ThromboxanesIBA 02/2011 - 12/2003
6	Epoprostenol (Prostacyclin)FDA LinkGeneric 10/2007 - 04/2002
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2008
5	Vasodilator Agents (Vasodilators)IBA 09/2021 - 01/2002
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 12/2018 - 09/2008
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2018 - 01/2002
5	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 11/2017 - 10/2004
5	Pharmaceutical PreparationsIBA 01/2017 - 08/2004
5	CollagenIBA 11/2015 - 12/2003
5	LipidsIBA 05/2015 - 05/2002
5	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2014 - 12/2003
5	Tyrosine Kinase InhibitorsIBA 01/2011 - 11/2008
5	ElementsIBA 05/2005 - 10/2002
4	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2022 - 01/2008
4	Matrix Metalloproteinases (MMPs)IBA 01/2019 - 09/2013
4	LipopolysaccharidesIBA 06/2018 - 10/2009
4	Fish OilsIBA 05/2015 - 05/2002
4	Soybean Oil FDA LinkGeneric 05/2015 - 05/2002
4	Tyrosine (L-Tyrosine)FDA Link 05/2015 - 01/2008
4	Platelet-Derived Growth FactorIBA 03/2013 - 01/2010
4	diethylstilbestrol monophosphate (PDES)IBA 02/2012 - 01/2010
4	Protein Isoforms (Isoforms)IBA 01/2010 - 04/2006
4	Arginine (L-Arginine)FDA Link 11/2009 - 10/2006
4	FibrinIBA 09/2004 - 07/2002
3	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 03/2022 - 05/2010
3	EnzymesIBA 01/2022 - 01/2008
3	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022 - 11/2009
3	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2021 - 07/2013
3	Tadalafil (Cialis)FDA Link 10/2020 - 10/2004
3	ChemokinesIBA 01/2020 - 06/2009
3	AcidsIBA 01/2020 - 05/2002
3	Guanosine Monophosphate (5' Guanylic Acid)IBA 01/2019 - 01/2004
3	pro-brain natriuretic peptide (1-76)IBA 01/2016 - 07/2013

Therapy/Procedure

35	Therapeutics 01/2022 - 04/2002
4	Endarterectomy (Thromboendarterectomy) 01/2017 - 07/2013
3	Immunotherapy 01/2022 - 03/2006
3	Immunomodulation 01/2020 - 02/2007
3	Catheters 10/2018 - 04/2002